Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

### DOSAGE AND ADMINISTRATION

- **The recommended dosage of Xermelo in adult patients is 250 mg three times daily for patients whose diarrhea is inadequately controlled by a SSA therapy.**

- **Take Xermelo with food.**

- **When short-acting octreotide is used in combination with Xermelo, administer short-acting octreotide at least 30 minutes after administering Xermelo.**

- **Discontinue Xermelo if severe constipation develops.**

### WARNINGS AND PRECAUTIONS

- **History of hypersensitivity to telotristat.**

### ADVERSE REACTIONS

Most common adverse reactions (≥5%) are nausea, headache, increased GGT, depression, flatulence, decreased appetite, peripheral edema, and pyrexia.

### DRUG INTERACTIONS

CYP3A4 Substrates (e.g., midazolam) and CYP2B6 Substrates (e.g., bupropion, efavirenz): Efﬁcacy of concomitant drugs may be decreased; monitor patients’ response and consider increasing the dosage of the concomitant drug, if necessary.

### PATIENT COUNSELING INFORMATION

Revised: 9/2022

---

### DOSE Forms and STRENGTHs

<table>
<thead>
<tr>
<th>Tablets: 250 mg telotristat ethyl</th>
<th>7.1 CYP3A4 Substrates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7.2 CYP2B6 Substrates</td>
</tr>
<tr>
<td></td>
<td>7.3 Short-Acting Octreotide</td>
</tr>
</tbody>
</table>

### INDICATIONS and UsE

1. **INDICATIONS and Usage**

   Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

2. **Dosage and Administration**

   The recommended dosage of Xermelo in adult patients is 250 mg three times daily for patients whose diarrhea is inadequately controlled by SSA therapy.

3. **Dosage Forms and Strengths**

   Tablets: 250 mg telotristat ethyl, white to off-white, coated and oval with “T-E” debossed on one side and “250” debossed on the other side.

4. **Contraindications**

   Xermelo is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash, and pruritis.

5. **Warnings and Precautions**

   5.1 Constipation

   Xermelo reduces bowel movement frequency and may lead to constipation. Serious complications of constipation have been reported during clinical trials and postmarketing.

   In a 12-week, placebo-controlled trial, in which patients had 4 or greater bowel movements per day, 2 out of 45 patients treated with a higher than recommended dosage of Xermelo reported constipation. In one patient the constipation was serious, resulting in hospitalization. During the 36-week extension period with higher than the recommended dosage of Xermelo, 10 of 115 patients reported constipation, with individual reports of intestinal perforation, obstruction, and fecaloma. In another 12-week, placebo-controlled trial in which patients had less than 4 bowel movements per day, 4 out of 25 patients treated with the recommended dosage of Xermelo reported constipation.

   Serious complications of constipation in patients treated with Xermelo at the recommended dosage (e.g., intestinal obstruction) have also been reported in the postmarketing setting. Most patients had additional risk factors, including underlying disease and concomitant constipating medications.

   Given that patients with metastatic carcinoid tumors may have impaired integrity of the gastrointestinal tract wall, monitor for the development of constipation and/or severe, persistent, or worsening abdominal pain in patients taking Xermelo. Discontinue Xermelo if severe constipation or severe persistent or worsening abdominal pain develops.

6. **Adverse Reactions**

   6.1 Clinical Trials Experience

   Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

   Xermelo was studied in a double-blind, placebo-controlled clinical trial of 90 patients with metastatic neuroendocrine tumors and carcinoid syndrome diarrhea. Patients reported between 4 to 12 bowel movements daily despite the use of SSA therapy at a stable dose for at least 3 months.

   Adverse reactions occurring at an incidence of at least 5% in the Xermelo group (N=45) and at an incidence greater than placebo (N=45) during the 12-week placebo-controlled period of the trial:

   Table 1 below lists adverse reactions occurring at an incidence of at least 5% in the Xermelo group (N=45) and at an incidence greater than placebo (N=45) during the 12-week placebo-controlled period of the trial.

   Table 1: Percent Common Adverse Reactions by Treatment Group at 12-Weeks in a Double-Blind Placebo-Controlled Clinical Trial of Patients with Carcinoid Syndrome Diarrhea

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Xermelo 250 mg Three Times Daily, N=45 (%)</th>
<th>Placebo, N=45 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>13</td>
<td>11</td>
</tr>
<tr>
<td>Headache</td>
<td>11</td>
<td>4</td>
</tr>
<tr>
<td>Increased gamma-glutamyl-transferase (GGT)</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Depression</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Flatulence</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>7</td>
<td>4</td>
</tr>
</tbody>
</table>

*incidence of at least 5% in the Xermelo group and at an incidence greater than placebo

*including depression, depressed mood and decreased interest
In another placebo-controlled clinical trial of patients with carcinoid syndrome diarrhea and less than 4 bowel movements per day, the following additional adverse reactions, not listed in Table 1, of abdominal pain (including upper and lower abdominal pain, abdominal distention and gastrointestinal pain) and constipation were reported in at least 5% of patients in the Xermelo treated group and at an incidence greater than placebo [see Warnings and Precautions (5.1)].

Less Common Adverse Reactions:
The following is a list of adverse reactions occurring in less than 5% of patients receiving Xermelo during the 12-week placebo-controlled period of the clinical trial:

- increased alkaline phosphatase, increased alanine aminotransferase, and increased aspartate aminotransferase.
- Fecaloma was reported in one patient treated with Xermelo (at a higher than recommended dosage) during the 36-week open-label extension period following the 12-week double-blind period of the trial.

6.2 Postmarketing Experience
The following adverse reactions have been identified during post approval use of Xermelo. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- Gastrointestinal: intestinal obstruction [see Warnings and Precautions (5.1)]
- Immune system disorders: angioedema
- Skin and subcutaneous tissue disorders: pruritis, rash

7 DRUG INTERACTIONS

7.1 CYP3A4 Substrates
Concomitant use of Xermelo may decrease the efficacy of drugs that are CYP3A4 substrates (e.g., midazolam) by decreasing their systemic exposure. Monitor patients’ response to CYP3A4 substrates when co-administered with Xermelo and consider increasing the dosage of the interacting drug, if necessary [see Clinical Pharmacology (12.3)].

7.2 CYP2B6 Substrates
Concomitant use of Xermelo may decrease the efficacy of drugs that are CYP2B6 substrates (e.g., bupropion, efavirenz) by decreasing their systemic exposure. Monitor patients’ response to CYP2B6 substrates when co-administered with Xermelo and consider increasing the dosage of the interacting drug, if necessary [see Clinical Pharmacology (12.3)].

7.3 Short-Acting Octreotide
Concurrent administration of short-acting octreotide with Xermelo significantly decreased the systemic exposure of telotristat ethyl and telotristat, the active metabolite. If treatment with short-acting octreotide is needed in combination with Xermelo, administer short-acting octreotide at least 30 minutes prior to administration of Xermelo [see Clinical Pharmacology (12.3)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
Risk Summary

There is no human data with Xermelo use in pregnant women to inform a drug-associated risk.

In animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral telotristat ethyl to rats during organogenesis at doses up to 750 mg/kg/day (approximately 9 times the exposure at the RHD) and up to 150 mg/kg/day (approximately 3 times the exposure at the RHD). In a pre-/postnatal development study, no increased incidence of mortality in rat offspring was observed during postnatal days 0 to 4 at the maternal oral dose of 500 mg/kg/day (approximately 5 times the exposure at the RHD), given during organogenesis through lactation [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal data

An embryo-fetal development study performed in rats with oral telotristat ethyl at doses up to 750 mg/kg/day (approximately 9 times the AUC [area under the plasma concentration-time curve] for the active metabolite at the RHD) during organogenesis produced no harm to embryo-fetal development. In pregnant rabbits treated orally with telotristat ethyl during organogenesis, an increased incidence of post-implantation loss at doses of 250 mg/kg/day or higher (approximately 15 times the exposure at the RHD), and reduced fetal weight at 500 mg/kg/day (approximately 33 times the exposure at the RHD), were observed [see Data].

In a pre-/postnatal development study, no increased incidence of mortality in rat offspring was observed during postnatal days 0 to 4 at the maternal oral dose of 500 mg/kg/day (approximately 5 times the exposure at the RHD), given during organogenesis through lactation [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

8.2 Lactation
Risk Summary

There are no data on the presence of telotristat ethyl in human or animal milk, the effects on the breastfed infant, or the effects on milk production. The effects of local gastrointestinal and systemic exposure to telotristat ethyl on breastfed infants are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Xermelo and any potential adverse effects on the breastfed infant from Xermelo or from the underlying maternal condition.

Clinical Considerations

Monitor the breastfed infant for symptoms of constipation.

8.4 Pediatric Use
The safety and effectiveness of Xermelo in pediatric patients have not been established.

8.5 Geriatric Use
Of 45 patients in a clinical trial of Xermelo, 19 (42%) patients were 65 years of age and over. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

8.6 Renal Impairment
No dosage adjustment of Xermelo is necessary in patients with mild, moderate or severe renal impairment who are not requiring dialysis.

There is no information on Xermelo in patients with end-stage renal disease who require dialysis (eGFR <15 mL/min/1.73 m²).

8.7 Hepatic Impairment
Systemic exposure of telotristat ethyl and its active metabolite, telotristat, were substantially increased in patients with moderate hepatic impairment (Child-Pugh Class B) and severe hepatic impairment (Child-Pugh C) (2.3- and 5.0-fold, respectively) compared to patients with normal hepatic function [see Clinical Pharmacology (12.3)]. Xermelo is not recommended in patients with moderate and severe hepatic impairment.

No dosage adjustment of Xermelo is necessary in patients with mild hepatic impairment (Child-Pugh A); however, additional monitoring of Xermelo-associated adverse reactions (e.g., constipation) is recommended in these patients [see Warnings and Precautions (5.1)].

11 DESCRIPTION

Xermelo (telotristat ethyl) tablets contain telotristat ethyl, a tryptophan hydroxylase inhibitor. Telotristat ethyl is the hippurate salt of telotristat ethyl [(S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate], which undergoes hydrolysis to the active metabolite, (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid.

The molecular formula of telotristat ethyl is C_{36}H_{37}ClF_{7}N_{6}O_{3} • C_{6}H_{5}NO_{5} and its molecular weight is 754.2. The molecular weight of the free base (telotristat ethyl) is 575.0.

Chemical Structure:

![Chemical Structure of Telotristat Ethyl](chart)

Telotristat ethyl is a white to off-white solid. The solubility is a function of pH at 25°C; at pH 1 (0.1N HCl), the solubility is greater than 71 mg/mL, at pH 3 phosphate buffer, the solubility is 0.30 mg/mL, at a pH of 5 to 9, the solubility is negligible. In organic solvents, telotristat ethyl is freely soluble in methanol, soluble in acetone, and sparingly soluble in ethanol.

Each Xermelo tablet contains 250 mg of telotristat ethyl (free base) which is equivalent to 328 mg telotristat ethyl. The inactive ingredients of Xermelo tablets include: colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl cellulose, lactose anhydrous, microgel/PEG, magnesium stearate, polyvinyl alcohol [part hydrolyzed], talc and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action
Telotristat, the active metabolite of telotristat ethyl, is an inhibitor of tryptophan hydroxylase, which mediates the rate limiting step in serotonin biosynthesis. In the in vitro inhibitory potency of telotristat towards tryptophan hydroxylase is 29 times higher than that of telotristat ethyl. Serotonin plays a role in mediating secretion, mobility, inflammation, and sensation of the gastrointestinal tract, and is over-produced in patients with carcinoid syndrome. Through inhibition of tryptophan hydroxylase, telotristat and telotristat ethyl reduce the production of peripheral serotonin, and the frequency of carcinoid syndrome diarrhea.

12.2 Pharmacodynamics

In healthy subjects, telotristat ethyl 500 mg three times daily (twice the recommended dosage) for 14 days decreased whole blood serotonin and 24-hour urinary 5-hydroxyindolacetic acid (u5-HIAA) from baseline. A decrease in 24-hour u5-HIAA was observed as early as after 5 days of treatment. In patients with metastatic neuroendocrine tumors and carcinoid syndrome diarrhea, 24-hour u5-HIAA decreased from baseline following 6 and 12 weeks of treatment with Xermelo 250 mg three times a day, whereas placebo did not decrease u5-HIAA.

Cardiac Electrophysiology

At a dose 6 times the recommended dose of 250 mg, Xermelo does not prolong the QT interval to any clinically relevant extent.

12.3 Pharmacokinetics

Absorption

After a single oral dose of telotristat ethyl to healthy subjects, telotristat ethyl was absorbed and metabolized to its active metabolite, telotristat. Peak plasma concentrations of telotristat ethyl were achieved within 0.5 to 2 hours, and those of telotristat within 1 to 3 hours. Plasma concentrations thereafter declined in a biphasic manner. Following administration of a single 500 mg dose of telotristat ethyl...
ethyl (twice the recommended dosage) under fasted conditions in healthy subjects, the mean Cmax and AUCinf of telotristat were 4.4 ng/mL and 6.23 ng•hr/mL, respectively, for telotristat ethyl. The mean Cmax and AUCinf were increased by 22% and 111%, respectively, for telotristat ethyl. The pharmacokinetic parameters for both telotristat ethyl and telotristat were highly variable with about 55% coefficient of variation.

Following multiple-dose administration of telotristat ethyl 500 mg three times daily, there was negligible accumulation at steady state for both telotristat ethyl and telotristat. In patients with metastatic neuroendocrine tumors and carcinoid syndrome diarrhea treated with SSA therapy, the median Tmax for telotristat ethyl and telotristat was approximately 1 and 2 hours, respectively.


**Drug Interaction Studies**

**Effect of Telotristat Ethyl on Other Drugs**

**Midazolam**

Following administration of multiple doses of telotristat ethyl, the systemic exposure to concomitant midazolam was significantly decreased. When 3 mg midazolam was co-administered orally after 5 day treatment with telotristat ethyl 500 mg three times daily (twice the recommended dosage), the mean Cmax and AUCinf for midazolam were decreased by 25%, and 48%, respectively, compared to administration of midazolam alone. The mean Cmax and AUCinf for the active metabolite, 1-hydroxymidazolam, were also decreased by 34%, and 48%, respectively. The reduction in the systemic exposure to both midazolam and its active metabolite suggests that the glucuronidation of 1-hydroxymidazolam may have been increased by telotristat ethyl [see Drug Interactions (7.1)].

**Fexofenadine**

In vitro telotristat ethyl, but not telotristat, inhibited P-glycoprotein (P-gp). In healthy volunteers, the Cmax and AUC of fexofenadine increased by 16% when a single 180 mg dose of fexofenadine was co-administered orally with the final dose of telotristat ethyl 500 mg administered three times daily (twice the recommended dosage) for 5 days. Clinically meaningful interactions with P-gp substrates are unlikely.

**Effect of Other Drugs on Telotristat Ethyl**

**Short-Acting Opioid**

Gastric Acid Reducers (Proton Pump Inhibitor and H2-Receptor Antagonist)

Omeprazole: The Cmax and AUC of telotristat ethyl were increased by 68% and 185%, respectively, when a single 250 mg dose of Xermelo was coadministered with a 40 mg dose of omeprazole once daily compared to administration of Xermelo alone. No significant change (<9%) in AUC and Cmax of the active metabolite, telotristat, was observed following coadministration of Xermelo with omeprazole compared to administration of Xermelo alone. These changes in exposure of telotristat ethyl and telotristat are not considered to be clinically meaningful.

**Famotidine**

The Cmax and AUC of telotristat ethyl were increased by 22% and 111%, respectively, when a single 250 mg dose of Xermelo was coadministered with a 40 mg dose of famotidine twice daily. No significant change (<5%) in AUC and Cmax to the active metabolite, telotristat, was observed following coadministration of Xermelo with famotidine compared to administration of Xermelo alone. These changes in exposure are not considered to be clinically meaningful.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 26-week study in transgenic (Tg.rash2) mice, telotristat ethyl was not tumorigenic at oral doses up to 300 mg/kg/day (approximately 12 to 19 times the AUC for the active metabolite at the RHD). In a 2-year carcinogenicity study in Sprague-Dawley rats, telotristat ethyl was not tumorigenic at oral doses up to 170 mg/kg/day (approximately 2 to 5 times the AUC for the active metabolite at the RHD).

Telotristat ethyl was negative in the in vivo Ames test, the in vitro chromosomal aberration test using Chinese hamster ovary cells, and the in vivo rat micronucleus test.

Telotristat ethyl at oral doses up to 500 mg/kg/day (approximately 5 times the AUC for the active metabolite at the RHD) was found to have no effect on fertility and reproductive performance of male or female rats.

14 CLINICAL STUDIES

A 12-week double-blind, placebo-controlled, randomized, multicenter trial of Xermelo was conducted in adult patients with a well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea who were having between 4 to 12 daily bowel movements despite the use of SSA therapy at a stable dose for at least 3 months. Patients were randomized to placebo or treatment with Xermelo 250 mg three times daily.

Study medication was administered within 15 minutes before or within 1 hour after a meal or snack [see Dosage and Administration (2)]. All patients were required to stay on their baseline SSA regimen and were allowed to use rescue medication (short-acting octreotide) and antidiarheals (e.g., loperamide) for symptomatic relief. A total of 90 patients were evaluated for efficacy. The mean age of the population was 63 years of age (range 37 to 83 years), 50% were male, and 90% were White. The primary efficacy endpoint was the change from baseline in the number of daily bowel movements averaged over the 12-week treatment period. The analysis results can be found in Table 2 below. The average was based on the number of days with valid, non-missing data. When a patient had more than 6 weeks of missing data, the change from baseline was considered equal to zero. Week with missing data was defined as a patient missing at least 4 days of dietary data in that week.
Table 2: Change from Baseline in Bowel Movements/Day Averaged Over 12 Weeks in Adult Patients with Carcinoid Syndrome Diarrhea

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Xermelo 250 mg three times daily</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bowel Movements/Day at Baseline</td>
<td>45</td>
<td>45</td>
</tr>
<tr>
<td>Baseline Mean (SD) Median (Min, Max)</td>
<td>6.1 (2.1)</td>
<td>5.2 (1.4)</td>
</tr>
<tr>
<td>Baseline Mean (SD) Median (Min, Max)</td>
<td>5.5 (3.5, 13.0)</td>
<td>5.1 (3.5, 9.0)</td>
</tr>
<tr>
<td>Change Averaged over 12 Weeks: Mean (SD) Median (Min, Max)</td>
<td>-1.4 (1.4)</td>
<td>-0.6 (0.8)</td>
</tr>
<tr>
<td>Change Averaged over 12 Weeks: Mean (SD) Median (Min, Max)</td>
<td>-1.3 (-6.1, 1.6)</td>
<td>-0.6 (-2.7, 0.8)</td>
</tr>
<tr>
<td>Estimate of Treatment Difference (97.5% CL)</td>
<td>-0.8c</td>
<td>- —</td>
</tr>
</tbody>
</table>

CL=confidence limit; SD=standard deviation.

a Baseline Bowel Movements/Day was assessed over the 3-4 week screening/run-in period.

b Statistical tests used a blocked 2-sample Wilcoxon Rank Sum statistic (van Elteren test) stratified by the u5-HIAA stratification at randomization. CLs were based on the Hodges-Lehmann estimator of the median paired difference.

c p<0.001

In the 12-week study, a difference in average weekly reductions in bowel movement frequency between Xermelo and placebo was observed as early as 1 to 3 weeks, and persisted for the remaining 9 weeks of the study.

To aid in the interpretation of the bowel movement reduction results, the proportion of patients reporting any particular level of reduction in overall average bowel movement frequency is depicted in Figure 1 below. For example, 33% of patients randomized to Xermelo and 4% of patients randomized to placebo experienced a reduction in overall average bowel movements from baseline of at least 2 bowel movements per day.

Figure 1: Cumulative Proportion of Patients with Carcinoid Syndrome Diarrhea Reporting Change in Overall Average Bowel Movement Frequency

Other symptoms of carcinoid syndrome (abdominal pain or flushing) did not show improvement in the comparison of Xermelo to placebo.

The average number of daily short-acting octreotide injections used for rescue therapy over the 12-week double-blind treatment period was 0.3 and 0.7 in the Xermelo and placebo groups, respectively. In the subgroup of patients who received short-acting octreotide injections, observed reductions in the number of bowel movements per day and treatment differences were generally consistent with the reductions and differences observed in patients who did not receive rescue therapy, and were similar to the overall data presented in Table 2 above [see Dosage and Administration (2), Drug Interactions (7.2)].

A third randomized treatment arm of Xermelo 500 mg three times daily did not demonstrate additional treatment benefit on the primary endpoint and had a greater incidence of adverse reactions than Xermelo 250 mg three times daily. Therefore, Xermelo 500 mg three times daily is not recommended [see Dosage and Administration (2)].

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

250 mg tablet: white to off-white coated oval tablet with “T-E” debossed on one side and “250” debossed on the other side.

Xermelo is dispensed in a monthly case for a total of 28 days of therapy. Each monthly case contains four weekly packs. Each weekly pack contains 21 tablets.


Storage

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise patients:

- If they experience severe constipation or severe persistent or worsening abdominal pain, to discontinue Xermelo and contact their healthcare provider [see Warnings and Precautions (5.1)].
- To take Xermelo with food [see Clinical Pharmacology (12.3), Clinical Studies (14)].
- When short-acting octreotide is used in combination with Xermelo, administer short-acting octreotide at least 30 minutes after administering Xermelo [see Drug Interactions (7.3)].
- If a dose is missed, take the next dose at the regular time. Do not take 2 doses at the same time to make up for a missed dose.

Figure 1: Cumulative Proportion of Patients with Carcinoid Syndrome Diarrhea Reporting Change in Overall Average Bowel Movement Frequency